Patents by Inventor Jayesh Kulkarni
Jayesh Kulkarni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
METHOD OF DELIVERY OF DNA OR RNA CARGO USING UNSHIELDED LIPID NANOPARTICLES AND COMPOSITIONS THEREOF
Publication number: 20250241858Abstract: The present disclosure provides unshielded lipid nanoparticles and a process that enables the production of such unshielded lipid nanoparticles, thereby overcoming previous challenges of making particles without causing aggregation thereof. The lipid nanoparticles comprise a nucleic acid cargo molecule; a sterol or a derivative thereof present at a content of at least 12 mol %; a neutral lipid, such as a phospholipid having a choline head group present at a content of between 22 mol % and 65 mol %; and an ionizable cationic amino lipid present at a content of between 15 mol % and 45 mol %; wherein the lipid nanoparticle is non-sterically stabilized with a hydrophilic polymer-lipid conjugate, or otherwise unshielded and wherein each mol % content is relative to total lipid present in the lipid nanoparticle.Type: ApplicationFiled: April 21, 2025Publication date: July 31, 2025Inventors: Daniel Kurek, Dominik Witzigmann, Jayesh Kulkarni -
Publication number: 20250222113Abstract: This application relates to lipid nanoparticles, which include: a helper lipid and an ionizable lipid, at least one lipid layer surrounding an interior having at least one aqueous portion, an encapsulated inorganic particle, and an agent of interest (e.g. therapeutic, diagnostic, or theranostic agents). The ionizable lipid is present at between 2 mol % and 30 mol % relative to total lipid. The agent of interest is a hydrophilic agent present in the at least one aqueous portion or is a lipophilic agent present in the at least one lipid layer. This application also relates to methods of making the lipid nanoparticle, as well as methods of using the lipid nanoparticle (e.g. for therapy or diagnostics), including using external stimuli (e.g. laser irradiation) to release the agent of interest.Type: ApplicationFiled: February 14, 2023Publication date: July 10, 2025Inventors: Pieter Cullis, Jayesh Kulkarni, Igor Jigaltsev, Yuen Yi Tam, Antoine Uzel, Morteza Hasanzadeh Kafshgari, Michel Meunier
-
Patent number: 12343429Abstract: The present disclosure provides unshielded lipid nanoparticles and a process that enables the production of such unshielded lipid nanoparticles, thereby overcoming previous challenges of making particles without causing aggregation thereof. The lipid nanoparticles comprise a nucleic acid cargo molecule; a sterol or a derivative thereof present at a content of at least 12 mol %; a neutral lipid, such as a phospholipid having a choline head group present at a content of between 22 mol % and 65 mol %; and an ionizable cationic amino lipid present at a content of between 15 mol % and 45 mol %; wherein the lipid nanoparticle is non-sterically stabilized with a hydrophilic polymer-lipid conjugate, or otherwise unshielded and wherein each mol % content is relative to total lipid present in the lipid nanoparticle.Type: GrantFiled: October 4, 2024Date of Patent: July 1, 2025Assignee: NanoVation Therapeutics Inc.Inventors: Daniel Kurek, Dominik Witzigmann, Jayesh Kulkarni
-
Patent number: 12343405Abstract: The present disclosure provides a lipid nanoparticle comprising: a nucleic acid cargo molecule; sterol or a derivative thereof present at elevated content; neutral lipid; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present at a content between 0.5 and 3 mol %, wherein each mol % content is relative to total lipid present in the lipid nanoparticle.Type: GrantFiled: March 8, 2024Date of Patent: July 1, 2025Assignee: Nano Vation Therapeutics Inc.Inventors: Kevin An, Daniel Kurek, Jayesh Kulkarni, Dominik Witzigmann
-
METHOD OF DELIVERY OF DNA OR RNA CARGO USING UNSHIELDED LIPID NANOPARTICLES AND COMPOSITIONS THEREOF
Publication number: 20250114306Abstract: The present disclosure provides unshielded lipid nanoparticles and a process that enables the production of such unshielded lipid nanoparticles, thereby overcoming previous challenges of making particles without causing aggregation thereof. The lipid nanoparticles comprise a nucleic acid cargo molecule; a sterol or a derivative thereof present at a content of at least 12 mol %; a neutral lipid, such as a phospholipid having a choline head group present at a content of between 22 mol % and 65 mol %; and an ionizable cationic amino lipid present at a content of between 15 mol % and 45 mol %; wherein the lipid nanoparticle is non-sterically stabilized with a hydrophilic polymer-lipid conjugate, or otherwise unshielded and wherein each mol % content is relative to total lipid present in the lipid nanoparticle.Type: ApplicationFiled: October 4, 2024Publication date: April 10, 2025Inventors: Daniel Kurek, Dominik Witzigmann, Jayesh Kulkarni -
Publication number: 20240383843Abstract: Provided is lipid and methods of making such lipid, the lipid having the structure of: each R is independently an alkyl of C12 to C16, each alkyl having 1 to 3 C?C double bonds, wherein at least one of the double bonds is of Z geometry; R? is an optional alkyl; W is O, NH or NR?, wherein R? is a C1 to C3 alkyl group, such as a methyl; X is either absent or present, and if present, X is O, NH, or the NR?; and Z is an alkylamino chain as defined by [—(CH2)m—NG1G2G3], wherein m is 1-5 and G1 and G2 are, independently, the C1 to C3 alkyl group, G3 is absent, a hydrogen or the C1 to C3 alkyl group.Type: ApplicationFiled: May 26, 2022Publication date: November 21, 2024Applicant: NanoVation Therapeutics Inc.Inventors: Marco A. Ciufolini, Fariba Saadati, Anthony C. Y. Tam, Daniel Kurek, Dominik Witzigmann, Jayesh Kulkarni
-
Publication number: 20240350676Abstract: Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.Type: ApplicationFiled: May 10, 2024Publication date: October 24, 2024Inventors: Blair Leavitt, Pieter Cullis, Terri Petkau, Austin Hill, Pamela Wagner, Jayesh Kulkarni
-
Publication number: 20240342315Abstract: Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.Type: ApplicationFiled: December 21, 2023Publication date: October 17, 2024Inventors: Blair Leavitt, Pieter Cullis, Terri Petkau, Austin Hill, Pamela Wagner, Jayesh Kulkarni
-
Publication number: 20240300914Abstract: Provided is lipid and methods of making such lipid having the structure of Formula A: each R is an alkyl having a carbon backbone of C12 to C16 having 1 to 3 C?C double bonds, at least one having Z-geometry; R? is an optional alkyl of C2 to C24 having 0 to 3 C?C double bonds; each R, and the R? alkyl group if present, is optionally substituted at one or more positions with a C1 to C3 alkyl; W and X are O or S; Y is absent and C1 and C2 are bonded, or Y is present and is a metheno, etheno or ethyno bridge optionally substituted with an alkylamino chain [—(CH2)m—NG1G2G3], wherein m is 1-5 and G1, G2 are, independently, C1 to C3 alkyl, G3 is absent, hydrogen or C1 to C3 alkyl, or wherein NG1G2G3 is a heterocycle; and Z and Z? are H or alkylamino.Type: ApplicationFiled: May 26, 2022Publication date: September 12, 2024Applicant: NanoVation Therapeutics Inc.Inventors: Marco A. Ciufolini, Fariba Saadati, Anthony C. Y. Tam, Daniel Kurek, Dominik Witzigmann, Jayesh Kulkarni
-
Publication number: 20240287015Abstract: Provided herein is a method for producing an ionizable lipid that comprises: (i) reacting fatty esters in a Claisen condensation reaction in the presence of a catalyst, the Claisen condensation employing a weak base and carried out at a temperature of between ?10 and 60 degrees Celsius to produce a ketoester; (ii) reacting the ketoester produced in step (i) under conditions to produce a ketone from the ketoester in one or more steps via a hydrolysis and decarboxylation of the ketoester; and (iii) preparing the ionizable lipid from the ketone thereof using one or more synthesis steps resulting in an addition of an ionizable head group moiety to (a) the ketone; or (b) an alcohol produced from an optional reduction of the ketone to produce the alcohol, thereby producing the ionizable lipid. The ionizable lipid produced in step (iii) may be formulated in a drug delivery vehicle.Type: ApplicationFiled: May 26, 2022Publication date: August 29, 2024Applicant: NanoVation Therapeutics Inc.Inventors: Marco A. Ciufolini, Fariba Saadati, Anthony C. Y. Tam, Daniel Kurek, Dominik Witzigmann, Jayesh Kulkarni
-
Publication number: 20240285544Abstract: The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from 30 mol % to 70 mol %; (iii) a ionizable, cationic lipid content of from 5 mol % to 50 mol %; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol % to 5 mol. Further provided is a lipid nanoparticle comprising encapsulated mRNA and 20 to 70 mol % of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. Further provided are methods of administration of such lipid nanoparticles.Type: ApplicationFiled: April 30, 2024Publication date: August 29, 2024Inventors: Daniel Kurek, Anthony Tam, Maunish Barvalia, Dominik Witzigmann, Jayesh Kulkarni
-
Publication number: 20240269323Abstract: The present disclosure provides a lipid nanoparticle comprising encapsulated DNA vector and 30 to 60 mol % of a neutral lipid selected from sphingomyelin and a phosphatidylcholine lipid, and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle comprising a core comprising an electron dense region and an aqueous portion surrounded at least partially by a lipid layer comprising a bilayer and the lipid nanoparticle exhibiting at least a 10% increase in gene expression in a disease site or the liver, spleen or bone marrow at any time point after 24 or 48 hours post-injection as compared to a lipid nanoparticle encapsulating DNA vector with an Onpattro-type formulation of ionizable lipid/DSPC/cholesterol/PEG-lipid at 50/10/38.5/1.5, mol:mol, wherein the gene expression is measured in an animal model by detection of green fluorescent protein (GFP) or luciferase. Further provided are methods of medical treatment and uses of such lipid nanoparticles.Type: ApplicationFiled: June 1, 2022Publication date: August 15, 2024Applicant: NanoVation Therapeutics Inc.Inventors: Jayesh Kulkarni, Daniel Kurek, Anthony C. Y. Tam, Kate E. R. Hollinshead, Dominik Witzigmann
-
Publication number: 20240207439Abstract: The present disclosure provides a lipid nanoparticle comprising: a nucleic acid cargo molecule; sterol or a derivative thereof present at elevated content; neutral lipid; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present at a content between 0.5 and 3 mol %, wherein each mol % content is relative to total lipid present in the lipid nanoparticle.Type: ApplicationFiled: March 8, 2024Publication date: June 27, 2024Inventors: Kevin An, Daniel Kurek, Jayesh Kulkarni, Dominik Witzigmann
-
Patent number: 12011507Abstract: The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from mol % to 70 mol %; (iii) a ionizable, cationic lipid content of from 5 mol % to 50 mol %; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol % to 5 mol. Further provided is a lipid nanoparticle preparation comprising lipid nanoparticles having encapsulated mRNA and 20 to mol % of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticles exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. The lipid nanoparticles have an electron dense region and a nitrogen-to-phosphate charge ratio of between 4 and 15.Type: GrantFiled: March 31, 2023Date of Patent: June 18, 2024Assignee: NanoVation Therapeutics Inc.Inventors: Daniel Kurek, Anthony Tam, Maunish Barvalia, Dominik Witzigmann, Jayesh Kulkarni
-
Patent number: 11980673Abstract: Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.Type: GrantFiled: October 9, 2019Date of Patent: May 14, 2024Assignee: The University of British ColumbiaInventors: Blair Leavitt, Pieter Cullis, Terri Petkau, Austin Hill, Pamela Wagner, Jayesh Kulkarni
-
Patent number: 11951177Abstract: The present disclosure provides a lipid nanoparticle comprising: a nucleic acid cargo molecule; sterol or a derivative thereof present at elevated content; neutral lipid; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present at a content between 0.5 and 3 mol %, wherein each mol % content is relative to total lipid present in the lipid nanoparticle.Type: GrantFiled: March 22, 2023Date of Patent: April 9, 2024Assignee: NanoVation Therapeutics Inc.Inventors: Kevin An, Daniel Kurek, Jayesh Kulkarni, Dominik Witzigmann
-
Patent number: 11865190Abstract: Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.Type: GrantFiled: September 9, 2022Date of Patent: January 9, 2024Assignee: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Blair Leavitt, Pieter Cullis, Terri Petkau, Austin Hill, Pamela Wagner, Jayesh Kulkarni
-
Publication number: 20230398082Abstract: The present disclosure provides a lipid nanoparticle for extrahepatic delivery of mRNA, the lipid nanoparticle comprising: (i) mRNA cargo; (ii) a phosphatidylcholine lipid content of from mol % to 70 mol %; (iii) a ionizable, cationic lipid content of from 5 mol % to 50 mol %; (iv) a sterol selected from cholesterol or a derivative thereof; and (v) a hydrophilic polymer-lipid conjugate that is present at a lipid content of 0.5 mol % to 5 mol. Further provided is a lipid nanoparticle preparation comprising lipid nanoparticles having encapsulated mRNA and 20 to mol % of a phosphatidylcholine lipid, an ionizable lipid; and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticles exhibiting at least a 10% increase in gene expression of the mRNA in vivo as measured in one or more extrahepatic organs or tissues. The lipid nanoparticles have an electron dense region and a nitrogen-to-phosphate charge ratio of between 4 and 15.Type: ApplicationFiled: March 31, 2023Publication date: December 14, 2023Inventors: Daniel Kurek, Anthony Tam, Maunish Barvalia, Dominik Witzigmann, Jayesh Kulkarni
-
Publication number: 20230302153Abstract: The present disclosure provides a lipid nanoparticle comprising: a nucleic acid cargo molecule; sterol or a derivative thereof present at elevated content; neutral lipid; an ionizable lipid; and a hydrophilic polymer-lipid conjugate present at a content between 0.5 and 3 mol %, wherein each mol % content is relative to total lipid present in the lipid nanoparticle.Type: ApplicationFiled: March 22, 2023Publication date: September 28, 2023Inventors: Kevin An, Daniel Kurek, Jayesh Kulkarni, Dominik Witzigmann
-
Publication number: 20230073819Abstract: Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.Type: ApplicationFiled: September 9, 2022Publication date: March 9, 2023Inventors: Blair Leavitt, Pieter Cullis, Terri Petkau, Austin Hill, Pamela Wagner, Jayesh Kulkarni